| name | ata-postmenopausal-gonadotrope-diagnosis |
| description | Diagnoses gonadotrope dysfunction in postmenopausal women by confirming absent high serum FSH and LH when not on hormone replacement therapy. Use when evaluating a postmenopausal woman for hypogonadism; triggers include postmenopausal woman with suspected hypogonadism. |
Diagnose gonadotrope dysfunction in postmenopausal women using FSH and LH
STEP 1 — Gather Information
Confirm postmenopausal status (age >50 years with ≥12 months amenorrhea), obtain serum FSH and LH levels, and verify the patient is not currently on hormone replacement therapy (HRT).
STEP 2 — Rule In / Rule Out
Are both serum FSH and LH within the normal/low range (i.e., not elevated)? If yes → proceed to Step 3; if either is high → rule out gonadotrope dysfunction (consider primary ovarian failure or laboratory error).
STEP 3 — Classify or Stratify
Diagnose gonadotrope dysfunction (central hypogonadism) based on persistently non‑elevated FSH and LH in a postmenopausal woman off HRT.
STEP 4 — Decide
Initiate appropriate gonadal hormone replacement therapy (e.g., estrogen/progestin) if symptomatic and no contraindications, and evaluate for other pituitary hormone deficiencies.
Clinical Guardrails / Mimics / Pitfalls
Do not diagnose if the patient is on HRT, as estrogen/progestin artificially suppresses FSH and LH. Avoid relying on a single random sample without confirming postmenopausal status. Consider confounding factors such as hyperprolactinemia, exogenous glucocorticoids, or acute illness that can lower gonadotropins. LH assays may have greater variability; interpret both FSH and LH together.
Concrete Clinical Example
A 58‑year‑old woman reports 18 months of amenorrhea, no HRT, and mild hot flashes. Serum FSH is 5 IU/L (mid‑normal) and LH is 4 IU/L (normal). Gonadotrope dysfunction is diagnosed; low‑dose transdermal estrogen is started for symptom relief after confirming no contraindications.
Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, doi:10.1210/jc.2016-2118
